XPH(300147)

Search documents
ST香雪2025年中报简析:净利润同比下降72.96%,短期债务压力上升
Zheng Quan Zhi Xing· 2025-08-28 22:59
Core Viewpoint - ST Xiangxue reported disappointing financial results for the first half of 2025, with significant declines in revenue and net profit compared to the previous year [1][3]. Financial Performance - Total revenue for the first half of 2025 was 818 million yuan, a decrease of 25.4% year-on-year [1]. - The net profit attributable to shareholders was -234 million yuan, down 72.96% year-on-year [1]. - In Q2 2025, total revenue was 397 million yuan, a decline of 24.77% year-on-year, with a net profit of -146 million yuan, down 46.79% year-on-year [1]. Profitability Metrics - Gross margin was 28.53%, a decrease of 13.69% year-on-year [1]. - Net margin was -26.61%, a decline of 141.38% year-on-year [1]. - Total selling, administrative, and financial expenses amounted to 365 million yuan, accounting for 44.59% of revenue, an increase of 20.42% year-on-year [1]. Balance Sheet Indicators - Current ratio reached 0.27, indicating increased short-term debt pressure [1]. - Cash and cash equivalents were 96.22 million yuan, down 5.98% year-on-year [1]. - Accounts receivable increased to 903 million yuan, up 10.97% year-on-year [1]. Shareholder Metrics - Earnings per share were -0.35 yuan, a decrease of 75.0% year-on-year [1]. - Net asset value per share was 1.24 yuan, down 54.12% year-on-year [1]. - Operating cash flow per share was -0.07 yuan, a significant decline of 637.6% year-on-year [1]. Business Evaluation - The company's historical return on invested capital (ROIC) has been weak, with a median of 3.01% over the past decade [3]. - The worst year for ROIC was 2024, at -14.88%, indicating poor investment returns [3]. - The business model relies heavily on marketing-driven performance, necessitating further investigation into the underlying drivers [3]. Financial Health Indicators - Cash flow situation is concerning, with cash to current liabilities ratio at 1.98% and average operating cash flow to current liabilities at 3.5% over the past three years [3]. - Debt situation is also alarming, with interest-bearing debt ratio at 29.73% and total interest-bearing debt to average operating cash flow ratio at 12.98% [3]. - Financial expenses are high, with financial expenses to average operating cash flow ratio at 136.16% [3].
ST香雪(300147.SZ)发布上半年业绩,归母净亏损2.34亿元,扩大72.96%

智通财经网· 2025-08-27 14:29
Core Viewpoint - ST Xiangxue reported a significant decline in revenue and an increase in net losses for the first half of 2025, indicating financial distress and operational challenges [1] Financial Performance - The company's operating revenue for the first half of 2025 was 818 million yuan, a year-on-year decrease of 25.40% [1] - The net loss attributable to shareholders of the listed company was 234 million yuan, which represents a year-on-year increase of 72.96% [1] - The net loss attributable to shareholders after deducting non-recurring gains and losses was 207 million yuan, reflecting a year-on-year increase of 91.43% [1] - The basic loss per share was 0.35 yuan [1]
ST香雪(300147) - 2025年半年度非经营性资金占用及其他关联资金往来情况汇总表
2025-08-27 12:35
广州市香雪制药股份有限公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 单位:万元 非经营性资金占用 资金占用方名称 占用方与上 市公司的关 联关系 上市公司核算的 会计科目 2025 年期初 占用资金余额 2025 年度占用累 计发生金额(不含 利息) 2025 年度占用 资金的利息(如 有) 2025 年度偿还 累计发生金额 2025 年期末占 用资金余额 占用形成原 因 占用性质 控股股东、实际控 制人及其附属企业 广州市昆仑投资有限公 司 控股股东 其他应收款 363.62 0 4.30 367.92 0 资金占用 非经营性占用 小计 - - - 363.62 0 4.30 367.92 0 - 非经营性占用 前控股股东、实际 控制人及其附属企 业 — — 小计 - - - - - - - - - — 其他关联方及附属 企业 — 小计 - - - - - - - - - — 总计 - - - 363.62 0 4.30 367.92 0 - — 其它关联资金往来 资金往来方名称 往来方与上 市公司的关 联关系 上市公司核算的 会计科目 2025 年期初 往来资金余额 2025 年度 ...
ST香雪(300147) - 监事会决议公告
2025-08-27 12:32
广州市香雪制药股份有限公司 本公司及监事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 广州市香雪制药股份有限公司(以下简称"公司")第九届监事会第二十一 次会议于 2025 年 8 月 27 日在公司本部会议室以现场方式召开,会议通知已于 2025 年 8 月 15 日以邮件等方式送达了全体监事,会议应到监事三名,实到监事 三名,无委托出席的情况,会议由监事会主席黄伟华女士主持。本次会议的召开、 议事方式和表决程序符合《中华人民共和国公司法》和《公司章程》对召开监事 会的规定,与会监事认真审议会议议案,经表决方式通过并作出如下决议: 一、审议通过了《关于<2025 年半年度报告>及其摘要的议案》 经审核,监事会认为:公司《2025 年半年度报告》及其摘要的编制和审核 程序符合法律、行政法规、中国证监会和深圳证券交易所的规定,所披露的信息 真实、准确、完整的反映了公司 2025 年半年度经营的实际情况,不存在任何虚 假记载、误导性陈述或者重大遗漏。 证券代码:300147 证券简称:ST 香雪 公告编号:2025-041 第九届监事会第二十一次会议决议公告 具体内容详见巨 ...
ST香雪(300147) - 董事会决议公告
2025-08-27 12:30
证券代码:300147 证券简称:ST 香雪 公告编号:2025-040 广州市香雪制药股份有限公司 第九届董事会第二十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 本议案已经公司董事会审计委员会审议通过。 具体内容详见公司在巨潮资讯网披露的《2025 年半年度报告》及《2025 年 半年度报告摘要》。 表决结果:同意 6 票、反对 0 票、弃权 0 票。 特此公告。 广州市香雪制药股份有限公司董事会 2025 年 8 月 27 日 广州市香雪制药股份有限公司(以下简称"公司")第九届董事会第二十九 次会议于 2025 年 8 月 27 日在公司本部会议室以现场结合通讯方式召开,会议通 知已于 2025 年 8 月 15 日以邮件等方式送达了全体董事。会议应参加董事六名, 实际参加董事六名,独立董事吴杰先生、周庆权先生、陶剑虹女士以通讯方式出 席,无委托出席的情况,会议由董事长王永辉先生主持,公司监事和高级管理人 员等相关人员列席了本次会议。本次会议的召开符合《中华人民共和国公司法》 和《公司章程》的规定,经表决方式通过并作出如下决议: 一 ...
ST香雪:预重整进程稳步推进,子公司已获5个TCR-T产品IND批件
Zheng Quan Shi Bao Wang· 2025-08-27 12:20
Group 1 - The company reported a net loss of 234 million yuan in the first half of 2025, with total revenue of 818 million yuan, impacted by underperformance in traditional Chinese medicine sales, high financial costs, heavy asset burdens, and impairment provisions [1] - The company is focusing on R&D as a breakthrough point, particularly in the development of TCR-T products, which may help transition from traditional Chinese medicine to innovative pharmaceuticals, establishing a new competitive advantage in R&D [1] - TCR-T therapy, which modifies patients' T cells to target and kill tumor cells, shows better potential in efficacy and safety compared to the more familiar CAR-T therapy [1] Group 2 - The company’s subsidiary, Xiangxue Life Sciences, has received five clinical trial notifications for TCR-T products, with TAEST16001 injection approved for three indications: advanced soft tissue sarcoma, advanced esophageal cancer, and advanced non-small cell lung cancer [2] - The company has established a leading-edge biopharmaceutical R&D base and a complete TCR-T technology platform and process [2] - Traditional Chinese medicine products still hold significant brand and product advantages, with Xiangxue antiviral oral liquid being the first in the country to complete randomized double-blind placebo-controlled clinical research for cold symptoms [2] Group 3 - The company is currently progressing steadily in its pre-restructuring process, with auditing and evaluation work proceeding smoothly [3] - Entering the pre-restructuring program facilitates early communication with creditors and potential investors, allowing the company to gather feedback and develop a feasible restructuring plan [3] - The company will continue to manage daily operations actively, regardless of whether it enters the restructuring process [3]
香雪制药(300147) - 2025 Q2 - 季度财报
2025-08-27 11:40
广州市香雪制药股份有限公司 2025 年半年度报告全文 广州市香雪制药股份有限公司 2025 年半年度报告 2025-042 2025 年 08 月 1 广州市香雪制药股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别 和连带的法律责任。 公司负责人王永辉、主管会计工作负责人卢锋及会计机构负责人(会计主 管人员)郑重声明:保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中涉及未来计划、发展战略等前瞻性描述不构成公司对投资者的实 质承诺,投资者及相关人士均应对此保持足够的风险认识,并理解计划、预测 和承诺之间的差异。 公司已在本报告第三节"管理层讨论与分析"之"十、公司面临的风险和 应对措施"部分,详细描述了公司经营中可能存在的风险,敬请广大投资者予 以关注,注意投资风险。 二、报告期内在中国证监会指定网站上公开披露过的所有公司文件的正本及公告的原稿。 三、经公司法定代表人签名的 2025 年半年度报告原 ...
683只股短线走稳 站上五日均线
Zheng Quan Shi Bao Wang· 2025-08-26 08:45
Market Overview - The Shanghai Composite Index closed at 3868.38 points, above the five-day moving average, with a decline of 0.39% [1] - The total trading volume of A-shares reached 27098.31 billion yuan [1] Stocks Exceeding Five-Day Moving Average - A total of 683 A-shares have surpassed the five-day moving average today [1] - Notable stocks with significant deviation rates include: - Jiaheng Jiahua with a deviation rate of 14.97% and a price increase of 20.02% [2] - Jiuqi Co. with a deviation rate of 14.66% and a price increase of 19.99% [2] - Tianrun Technology with a deviation rate of 10.73% and a price increase of 13.75% [2] Additional Stocks with Positive Performance - Other stocks showing positive performance include: - Maide Medical with a deviation rate of 10.11% and a price increase of 15.55% [2] - Haosheng Electronics with a deviation rate of 8.86% and a price increase of 12.12% [2] - Wanbond with a deviation rate of 7.93% and a price increase of 9.97% [2] Summary of Deviation Rates - The table lists various stocks with their respective deviation rates, trading volumes, and price changes, indicating a general upward trend among selected stocks [2][3]
2025年粤港澳大湾区(阳山)“香雪制药杯”第二届匹克球公开赛落幕
Zhong Guo Xin Wen Wang· 2025-08-24 12:41
Group 1 - The 2025 Guangdong-Hong Kong-Macao Greater Bay Area (Yangshan) "Xiangxue Pharmaceutical Cup" Second Pickleball Open concluded on August 24 in Qingyuan City, Yangshan County [1] - The mixed team competition showcased strong performances from various teams, highlighting athletes' skills and training [2] - The champions of the mixed team competition were the Foshan Pickleball Association, with Guangdong Xiwang team as the runner-up and Yangshan Jierui Pickleball team securing third place [2] Group 2 - In the parent-child competition, the "Bear Out" team won the championship, while "Xili Chuqin" team and "Meteor Garden" team finished as the runner-up and third place respectively [2] - The atmosphere of the event was praised, with participants expressing a desire for more opportunities to engage in such competitions [2][3] - Participants noted the positive experience and learning opportunities provided by the event, emphasizing the friendly environment and the chance to improve skills [2]
2025年粤港澳大湾区(阳山)“香雪制药杯”第二届匹克球公开赛开赛
Zhong Guo Xin Wen Wang· 2025-08-23 10:13
Group 1 - The 2025 Guangdong-Hong Kong-Macao Greater Bay Area "Xiangxue Pharmaceutical Cup" second pickleball open tournament commenced on August 23 in Yangshan County, attracting 32 mixed team and 16 parent-child teams from across the country [1][3] - The tournament features two events: mixed team competition and parent-child competition, highlighting the growing popularity of pickleball in the region [1][3] - Participants expressed excitement about competing at a high level and the opportunity to learn and improve their skills through interaction with teams from different areas [3] Group 2 - The event showcased impressive athletic performances, including precise serves, powerful smashes, and seamless teamwork, which captivated the audience [3] - Local athletes expressed pride in participating in a large-scale tournament and emphasized the importance of such events for enhancing the local pickleball culture [3] - The tournament is seen as a significant opportunity for athletes to gain experience and recognize areas for improvement in their game [3]